JP6426599B2 - 乳汁分泌の管理用のペプチド - Google Patents
乳汁分泌の管理用のペプチド Download PDFInfo
- Publication number
- JP6426599B2 JP6426599B2 JP2015501047A JP2015501047A JP6426599B2 JP 6426599 B2 JP6426599 B2 JP 6426599B2 JP 2015501047 A JP2015501047 A JP 2015501047A JP 2015501047 A JP2015501047 A JP 2015501047A JP 6426599 B2 JP6426599 B2 JP 6426599B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amino acid
- seq
- peptide
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 144
- 235000013336 milk Nutrition 0.000 title claims description 69
- 239000008267 milk Substances 0.000 title claims description 69
- 210000004080 milk Anatomy 0.000 title claims description 69
- 102000004196 processed proteins & peptides Human genes 0.000 title description 39
- 230000028327 secretion Effects 0.000 title description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 77
- 150000001413 amino acids Chemical group 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 46
- 210000005075 mammary gland Anatomy 0.000 claims description 40
- 230000006651 lactation Effects 0.000 claims description 34
- 238000004519 manufacturing process Methods 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 24
- 125000006239 protecting group Chemical group 0.000 claims description 21
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 16
- 239000004472 Lysine Substances 0.000 claims description 16
- 230000001939 inductive effect Effects 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 13
- 241000124008 Mammalia Species 0.000 claims description 12
- 150000001408 amides Chemical class 0.000 claims description 11
- 239000004475 Arginine Substances 0.000 claims description 8
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 8
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 150000002148 esters Chemical class 0.000 claims description 8
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 8
- 230000002459 sustained effect Effects 0.000 claims description 7
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000002955 immunomodulating agent Substances 0.000 claims description 4
- 229940121354 immunomodulator Drugs 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 238000011200 topical administration Methods 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 239000003899 bactericide agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 108010076119 Caseins Proteins 0.000 description 33
- 102000011632 Caseins Human genes 0.000 description 33
- 208000004396 mastitis Diseases 0.000 description 33
- 241000283690 Bos taurus Species 0.000 description 30
- 239000005018 casein Substances 0.000 description 28
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 28
- 235000021240 caseins Nutrition 0.000 description 28
- 238000011282 treatment Methods 0.000 description 21
- 230000008569 process Effects 0.000 description 20
- 239000000243 solution Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 210000000481 breast Anatomy 0.000 description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 239000008101 lactose Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 10
- 230000035611 feeding Effects 0.000 description 9
- 235000013350 formula milk Nutrition 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 210000001082 somatic cell Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000000038 chest Anatomy 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- YSZNURNVYFUEHC-BQBZGAKWSA-N Lys-Ser Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YSZNURNVYFUEHC-BQBZGAKWSA-N 0.000 description 6
- 101800005149 Peptide B Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000020256 human milk Nutrition 0.000 description 6
- 210000004251 human milk Anatomy 0.000 description 6
- 210000002445 nipple Anatomy 0.000 description 6
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical group OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- YDDDRTIPNTWGIG-SRVKXCTJSA-N Lys-Lys-Ser Chemical group [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O YDDDRTIPNTWGIG-SRVKXCTJSA-N 0.000 description 5
- 125000000539 amino acid group Chemical group 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108010001441 Phosphopeptides Proteins 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000001139 pH measurement Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940080237 sodium caseinate Drugs 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102000000591 Tight Junction Proteins Human genes 0.000 description 3
- 108010002321 Tight Junction Proteins Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 244000144980 herd Species 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 230000032696 parturition Effects 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 230000035935 pregnancy Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001578 tight junction Anatomy 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 238000003977 dairy farming Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 229950006137 dexfosfoserine Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000021055 solid food Nutrition 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HNXRLRRQDUXQEE-ALURDMBKSA-N (2s,3r,4s,5r,6r)-2-[[(2r,3s,4r)-4-hydroxy-2-(hydroxymethyl)-3,4-dihydro-2h-pyran-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC=C[C@H]1O HNXRLRRQDUXQEE-ALURDMBKSA-N 0.000 description 1
- QEVHRUUCFGRFIF-UHFFFAOYSA-N 6,18-dimethoxy-17-[oxo-(3,4,5-trimethoxyphenyl)methoxy]-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylic acid methyl ester Chemical compound C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 241001315286 Damon Species 0.000 description 1
- 101100533283 Dictyostelium discoideum serp gene Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 238000007630 basic procedure Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960003168 bronopol Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 235000021129 infant diet Nutrition 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 229940124561 microbicide Drugs 0.000 description 1
- 239000002855 microbicide agent Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- -1 morpholino, thiomorpholino Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 108010009004 proteose-peptone Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003751 purification from natural source Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000026777 severe mastitis Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000021247 β-casein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4732—Casein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Description
Lys−Lys−Ser(P)−Ser(P)−Ser(P)(配列番号2);Lys−Lys−Ser(P)−Ser(P)−Ser(P)−Lys(配列番号3);Lys−Lys−Ser(P)−Ser(P)−Ser(P)−Lys−Lys(配列番号4);Lys−Ser(P)−Ser(P)−Ser(P)−Lys−Lys(配列番号5);Lys− Ser(P)−Ser(P)−Ser(P)−Lys(配列番号6);Lys−Ser(P)−Ser(P)−Ser(P)(配列番号7);Ser(P)−Ser(P)−Ser(P)−Lys−Lys(配列番号8);およびSer(P)−Ser(P)−Ser(P)−Lys(配列番号9)からなる群から選択されるアミノ酸配列を含む。可能な形態のそれぞれは、本発明の個々の実施形態を表す。
定義
本発明を実施する好ましい態様
実施例1:ペプチド合成
実施例2:カゼイン加水分解物の調製
実施例3:合成ペプチドの配合
実施例4:単離したペプチドによる退縮誘発を調査するフィールド試験
試験デザイン
i)脱リン酸化ペプチド
ii)カゼイン加水分解物
処置群
症例群
対照群
(i)11頭のウシ(合計44の分房)を、20mLの注射剤を介して乳腺内から1回投与したカゼイン加水分解物(20mL)で処置した(約1.8mg/mLカゼイン加水分解物(CPP)、合計=20mLに対して36mgCPP)
(ii)6頭のウシ(24の分房)に乳腺内注射を介して生理食塩液(10mL)を投与した
除外基準
・乾乳期前の4週間内に乳房炎のためまたはいずれか他の状態のために抗生物質治療を受けたウシ
・完全に機能する4未満の分房を有するウシ
・非泌乳ウシ
・臨床乳房炎(痛み、赤み、乳腺中の膨張もしくは温感、異常な乳汁分泌、凹部、飼料摂取量の減少、全身の不快感または他の徴候など)の所見を有するウシ
・登録を妨げることを担当医師によって特定された他の健康状態を示しているウシ
・淘汰を意図されているウシ。
処置
サンプリングおよび測定値
サンプル数
結果
pH
ラクトース
体細胞数
Claims (33)
- 合成または組換えペプチドであって、式X1(n)−Ser(P)−Ser(P)−Ser(P)−X2(n)(配列番号1)の4〜7アミノ酸の配列からなり、前記式中、X1およびX2の少なくとも1つは正に荷電したアミノ酸であり、X2は存在する場合は正に荷電したアミノ酸であり、それぞれのnについてn=0、1または2であり、前記配列番号1の式はさらにC末端に保護基を含む、合成または組換えペプチド。
- 前記正に荷電したアミノ酸がリジン、アルギニンおよびヒスチジンからなる群から選択される、請求項1に記載の合成または組換えペプチド。
- 前記正に荷電したアミノ酸がリジンである、請求項2に記載の合成または組換えペプチド。
- 前記保護基がアミドおよびエステルから選択される、請求項1に記載の合成または組換えペプチド。
- 前記保護基がアミドである、請求項4に記載の合成または組換えペプチド。
- 前記ペプチドが配列番号2〜9のいずれか1つに記載のアミノ酸配列を含む、請求項1に記載の合成または組換えペプチド。
- 前記ペプチドが配列番号2に記載のアミノ酸配列を含む、請求項1に記載の合成または組換えペプチド。
- 前記ペプチドが配列番号2からなる、請求項1に記載の合成または組換えペプチド。
- 前記ペプチドが配列番号12に記載のアミノ酸配列を含む、請求項4に記載の合成または組換えペプチド。
- 前記ペプチドが配列番号12からなる、請求項4に記載の合成または組換えペプチド。
- 式X1(n)−Ser(P)−Ser(P)−Ser(P)−X2(n)(配列番号1)の4〜7アミノ酸の配列を含む治療有効量の合成または組換えペプチドと、薬学的に許容される希釈剤または担体とを含む医薬組成物であって、前記式中、X1およびX2の少なくとも1つは正に荷電したアミノ酸であり、X2は存在する場合は正に荷電したアミノ酸であり、それぞれのnについてn=0、1または2であり、前記配列番号1の式はさらにC末端に保護基を含む、医薬組成物。
- 前記配列番号1の前記正に荷電したアミノ酸がリジン、アルギニンおよびヒスチジンからなる群から選択される、請求項11に記載の医薬組成物。
- 前記正に荷電したアミノ酸がリジンである、請求項12に記載の医薬組成物。
- 前記保護基がアミドおよびエステルから選択される、請求項11に記載の医薬組成物。
- 前記組成物が配列番号2〜9のいずれか1つまたはその組み合わせに記載のアミノ酸配列を含むペプチドを含む、請求項11に記載の医薬組成物。
- 前記組成物が配列番号2のアミノ酸配列を有するペプチドを含む、請求項11に記載の医薬組成物。
- 前記組成物が配列番号12のアミノ酸配列を有するペプチドを含む、請求項11に記載の医薬組成物。
- 前記組成物がゲル剤、軟膏、クリーム剤、乳剤および経皮パッチ剤からなる群から選択される形態で局所投与用に配合される、請求項11に記載の医薬組成物。
- 前記組成物が非経口投与用に配合される、請求項11に記載の医薬組成物。
- 乳腺内投与用に配合される請求項19に記載の医薬組成物。
- 泌乳哺乳動物の乳腺において乳汁産生の一時的停止、乳汁産生の持続的停止または退縮を誘発するために使用する医薬組成物であって、前記医薬組成物は、式X1(n)−Ser(P)−Ser(P)−Ser(P)−X2(n)(配列番号1)の4〜7アミノ酸の配列を含む合成または組換えペプチドを有効量含み、前記式中、X1およびX2の少なくとも1つは正に荷電したアミノ酸であり、X2は存在する場合は正に荷電したアミノ酸であり、それぞれのnについてn=0、1または2であり、前記配列番号1の式はさらにC末端に保護基を含む、医薬組成物。
- 細菌感染症を予防する、治療する、および逆行させるための方法において使用するための医薬組成物であって、前記医薬組成物は、式X1(n)−Ser(P)−Ser(P)−Ser(P)−X2(n)(配列番号1)の4〜7アミノ酸の配列を含む合成または組換えペプチドを有効量含み、前記式中、X1およびX2の少なくとも1つは正に荷電したアミノ酸であり、X2は存在する場合は正に荷電したアミノ酸であり、それぞれのnについてn=0、1または2であり、前記配列番号1の式はさらにC末端に保護基を含む、医薬組成物。
- 前記配列番号1の前記正に荷電したアミノ酸がリジン、アルギニンおよびヒスチジンからなる群から選択される、請求項21または22に記載の医薬組成物。
- 前記正に荷電したアミノ酸がリジンである、請求項23に記載の医薬組成物。
- 前記保護基がアミドおよびエステルから選択される、請求項21または22に記載の医薬組成物。
- 前記泌乳哺乳動物が泌乳家畜動物および泌乳ヒトから選択される、請求項21または22に記載の医薬組成物。
- 前記医薬組成物は、乳腺が乳汁を分泌中に投与される、請求項21または22に記載の医薬組成物。
- 前記医薬組成物が搾乳または授乳が終わると同時に投与される、請求項21に記載の医薬組成物。
- 前記医薬組成物が約6時間、約8時間、約12時間、約16時間、約20時間、約24時間、約48時間または約72時間からなる群から選択される間隔で、2〜6回投与される、請求項21に記載の医薬組成物。
- 前記医薬組成物が一回投与される、請求項21に記載の医薬組成物。
- 前記医薬組成物が泌乳動物の少なくとも1つの乳腺に投与される、請求項21に記載の医薬組成物。
- 前記医薬組成物が乳腺の乳頭管に投与される、請求項31に記載の医薬組成物。
- 前記医薬組成物が抗生物質、殺菌剤、ステロイド性抗炎症剤および非ステロイド性抗炎剤または免疫調節薬ならびにワクチンからなる群から選択される抗菌剤をさらに含む、請求項21または22に記載の医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261612410P | 2012-03-19 | 2012-03-19 | |
US61/612,410 | 2012-03-19 | ||
PCT/IL2013/050214 WO2013140388A1 (en) | 2012-03-19 | 2013-03-08 | Peptides for management of lactation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2015516377A JP2015516377A (ja) | 2015-06-11 |
JP6426599B2 true JP6426599B2 (ja) | 2018-11-21 |
Family
ID=49221927
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015501047A Active JP6426599B2 (ja) | 2012-03-19 | 2013-03-08 | 乳汁分泌の管理用のペプチド |
Country Status (11)
Country | Link |
---|---|
US (1) | US9487557B2 (ja) |
EP (1) | EP2828281B1 (ja) |
JP (1) | JP6426599B2 (ja) |
CN (1) | CN104321336B (ja) |
AU (1) | AU2013236975B2 (ja) |
BR (1) | BR112014023087A8 (ja) |
CA (1) | CA2867557C (ja) |
ES (1) | ES2759980T3 (ja) |
IL (1) | IL234574B (ja) |
IN (1) | IN2014DN08610A (ja) |
WO (1) | WO2013140388A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102022118B1 (ko) * | 2019-01-07 | 2019-09-18 | 주식회사 아스트로젠 | 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물 |
CN111632128B (zh) * | 2019-02-14 | 2022-07-05 | 三凡生技研发股份有限公司 | 短链胜肽组合物在预防或治疗干眼症的应用 |
JP7441946B2 (ja) | 2019-11-28 | 2024-03-01 | ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー | 非ヒト動物の乾乳におけるsglt-2阻害剤の使用 |
EP4329790A1 (en) * | 2021-04-28 | 2024-03-06 | Mileutis Ltd. | Compositions and methods for modulating mammary disorders and conditions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6391849B1 (en) | 1999-11-19 | 2002-05-21 | Agricultural Research Organization, The Volcani Center | Method and pharmaceutical composition for disrupting lactation in a mammary gland and for treating and preventing mastitis |
WO2002072629A1 (en) * | 2001-03-09 | 2002-09-19 | Meiji Seika Kaisha, Ltd. | Immunopotentiators |
ZA200710374B (en) * | 2005-05-02 | 2009-06-24 | Mileutis Ltd | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof |
ES2400511T3 (es) * | 2005-05-02 | 2013-04-10 | Mileutis Ltd. | Composiciones farmacéuticas que comprenden péptidos derivados de la caseina y métodos para el uso de las mismas |
KR20100058541A (ko) * | 2007-08-15 | 2010-06-03 | 아뮤닉스 인코포레이티드 | 생물학적 활성 폴리펩티드의 특성을 변경하기 위한 조성물 및 방법 |
-
2013
- 2013-03-08 CN CN201380025974.9A patent/CN104321336B/zh active Active
- 2013-03-08 ES ES13764905T patent/ES2759980T3/es active Active
- 2013-03-08 AU AU2013236975A patent/AU2013236975B2/en active Active
- 2013-03-08 EP EP13764905.9A patent/EP2828281B1/en active Active
- 2013-03-08 IN IN8610DEN2014 patent/IN2014DN08610A/en unknown
- 2013-03-08 WO PCT/IL2013/050214 patent/WO2013140388A1/en active Application Filing
- 2013-03-08 CA CA2867557A patent/CA2867557C/en active Active
- 2013-03-08 BR BR112014023087A patent/BR112014023087A8/pt not_active Application Discontinuation
- 2013-03-08 JP JP2015501047A patent/JP6426599B2/ja active Active
- 2013-03-08 US US14/384,395 patent/US9487557B2/en active Active
-
2014
- 2014-09-10 IL IL234574A patent/IL234574B/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
ES2759980T3 (es) | 2020-05-12 |
IN2014DN08610A (ja) | 2015-05-22 |
AU2013236975B2 (en) | 2017-10-19 |
CA2867557A1 (en) | 2013-09-26 |
BR112014023087A2 (pt) | 2017-06-20 |
EP2828281A4 (en) | 2015-11-11 |
US9487557B2 (en) | 2016-11-08 |
CN104321336A (zh) | 2015-01-28 |
CA2867557C (en) | 2020-03-10 |
WO2013140388A1 (en) | 2013-09-26 |
CN104321336B (zh) | 2021-08-06 |
IL234574B (en) | 2020-09-30 |
BR112014023087A8 (pt) | 2018-01-16 |
EP2828281A1 (en) | 2015-01-28 |
US20150093400A1 (en) | 2015-04-02 |
AU2013236975A1 (en) | 2014-10-23 |
JP2015516377A (ja) | 2015-06-11 |
EP2828281B1 (en) | 2019-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5247429B2 (ja) | カゼイン由来ペプチドを含む医薬組成物及びその使用方法 | |
JP6426599B2 (ja) | 乳汁分泌の管理用のペプチド | |
JPH11512087A (ja) | ヒトの病理学及び生理学における、アドレノメジュリン(am)及び遺伝子関連産物(pamp)の機能的役割 | |
RU2708329C2 (ru) | Материал стволовых клеток, композиции и способы применения | |
AU2007237074A1 (en) | Livestock management for improved reproductive efficiency | |
JPH0247966B2 (ja) | ||
CN105283197B (zh) | 痤疮的治疗和预防 | |
AU2012200889B2 (en) | Pharmaceutical compositions comprising casein derived peptides and methods of use thereof | |
IL222487A (en) | Casein-derived peptides and methods for using them to increase milk yield | |
IL222486A (en) | Casein-derived peptides and methods for using them to enhance milk cleanliness | |
IL187120A (en) | Casein-derived peptides and methods for their use in the herd's interface with milk | |
JPH07309774A (ja) | 抗真菌剤 | |
TW200902046A (en) | Agents for preventing renal failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160307 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170228 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170525 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170727 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170817 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171226 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180525 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180925 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181025 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6426599 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |